These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 16280073)

  • 1. Subcutaneously administered Menopur, a new highly purified human menopausal gonadotropin, causes significantly fewer injection site reactions than Repronex in subjects undergoing in vitro fertilization.
    Keye WR; Webster B; Dickey R; Somkuti S; Crain J; Scobey MJ
    Reprod Biol Endocrinol; 2005 Nov; 3():62. PubMed ID: 16280073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneously administered Repronex in oligoovulatory female patients undergoing ovulation induction is as effective and well tolerated as intramuscular human menopausal gonadotropin treatment.
    Nichols J; Knochenhauer E; Fein SH; Nardi RV; Marshall DC
    Fertil Steril; 2001 Jul; 76(1):58-66. PubMed ID: 11438320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneously administered Repronex in female patients undergoing in vitro fertilization is as effective and well tolerated as intramuscular menotropin treatment. Repronex SC, IVF Study Group.
    Gocial B; Keye WR; Fein SH; Nardi RV
    Fertil Steril; 2000 Jul; 74(1):73-9. PubMed ID: 10899500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of mixed protocols with Bravelle (human-derived FSH) and Repronex (hMG) to assess clinical efficacy (EMBRACE) in women undergoing in vitro fertilization.
    Keye WR; Marrs RP; Check JH; Schnell V; Surrey M; Marshall DC;
    Fertil Steril; 2004 Aug; 82(2):348-57. PubMed ID: 15302283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, randomised, investigator-blind, controlled, clinical study on the clinical efficacy and tolerability of two highly purified hMG preparations administered subcutaneously in women undergoing IVF.
    Alviggi C; Cognigni GE; Morgante G; Cometti B; Ranieri A; Strina I; Filicori M; De Leo V; De Placido G
    Gynecol Endocrinol; 2013 Jul; 29(7):695-9. PubMed ID: 23638621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients.
    Hompes PG; Broekmans FJ; Hoozemans DA; Schats R;
    Fertil Steril; 2008 Jun; 89(6):1685-93. PubMed ID: 17681325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF).
    Alviggi C; Revelli A; Anserini P; Ranieri A; Fedele L; Strina I; Massobrio M; Ragni N; De Placido G
    Reprod Biol Endocrinol; 2007 Dec; 5():45. PubMed ID: 18053198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly purified human-derived follicle-stimulating hormone (Bravelle) has equivalent efficacy to follitropin-beta (Follistim) in infertile women undergoing in vitro fertilization.
    Dickey RP; Nichols JE; Steinkampf MP; Gocial B; Thornton M; Webster BW; Bello SM; Crain J; Marshall DC;
    Reprod Biol Endocrinol; 2003 Oct; 1():63. PubMed ID: 14609434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed protocols: multiple ratios of FSH and LH bioactivity using highly purified, human-derived FSH (BRAVELLE) and highly purified hMG (MENOPUR) are unaltered by mixing together in the same syringe.
    Scobey MJ; Raike E; Marshall DC
    Reprod Biol Endocrinol; 2005 Nov; 3():61. PubMed ID: 16280072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endometrin for luteal phase support in a randomized, controlled, open-label, prospective in-vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation.
    Doody KJ; Schnell VL; Foulk RA; Miller CE; Kolb BA; Blake EJ; Yankov VI
    Fertil Steril; 2009 Apr; 91(4):1012-7. PubMed ID: 18371963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha.
    Wechowski J; Connolly M; Schneider D; McEwan P; Kennedy R
    Fertil Steril; 2009 Apr; 91(4):1067-76. PubMed ID: 18339384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF.
    Ziebe S; Lundin K; Janssens R; Helmgaard L; Arce JC;
    Hum Reprod; 2007 Sep; 22(9):2404-13. PubMed ID: 17640944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical comparison of ovarian stimulation and luteal support agents in patients undergoing GnRH antagonist IVF cycles.
    Miller CE; Zbella E; Webster BW; Doody KJ; Bush MR; Collins MG
    J Reprod Med; 2013; 58(3-4):153-60. PubMed ID: 23539885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desensitization to urine-derived gonadotropins in a woman with secondary infertility.
    Koh YI; Choi IS; Lee HC; Na HS; Oh ST
    Ann Allergy Asthma Immunol; 2001 Nov; 87(5):434-8. PubMed ID: 11730189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous human menopausal gonadotropin administration for controlled ovarian hyperstimulation with intrauterine insemination cycles.
    Kaplan PF; Austin DJ; Freund R
    Am J Obstet Gynecol; 2000 Jun; 182(6):1421-6. PubMed ID: 10871458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A randomized, controlled trial comparing follicle stimulating hormone (FSH) to human menopausal gonadotropin (hMG) in fertilization in vitro].
    Daya S; Gumby J; Hughes EG; Collins JA; Sagle MA
    Contracept Fertil Sex; 1995 Dec; 23(12):766-71. PubMed ID: 8556078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
    Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
    Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of highly purified human menopausal gonadotropin in intra-uterine insemination.
    Groeneveld E; Kouijzer IJ; Timmermans AJ; Schats R; Hompes PG
    Eur J Obstet Gynecol Reprod Biol; 2011 Feb; 154(2):182-6. PubMed ID: 21093975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of human menopausal gonadotropin and follicle-stimulating hormone with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation in in vitro fertilization.
    Yang TS; Wang BC; Chang SP; Ng HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):452-6. PubMed ID: 7634183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.